Belgian Pharma UCB to Acquire US-Based Neurona for Up to $1.15 Billion

Belgian pharmaceutical company UCB has announced its intent to acquire US-based Neurona Therapeutics in a deal potentially worth up to $1.15 billion. The acquisition aims to expand UCB's portfolio in neurological treatments.